

## Attachment A

*Amgen v. Roche*  
05-cv-12237WGY

## MOTION TO ADMIT ROCHE ADMISSIONS

Tab	Ex.	Date	Description	Relevance
1.	BEG	11/17/2003	CERA Investor Telephone Conf., November 17, 2003	Infringement
2.	CQX	11/00/1998	[Roche does not object] Bailon et al., "Polyethylene Glycol-Conjugated Pharmaceutical Proteins," PSTT Vol. 1, No. 8, Nov. 1998.	Infringement
3.	EOE	08/20/2003	B. Bethell e-mail to M. Huber, Subject: SEP Phase I SAD Study, dated August 20, 2003	Infringement
4.	EOI	6/28/1995	Certified English Translation of Memo from Koll to Scherhag re Cangene - Pegyliertes EPO	Infringement
5.	EOJ	08/22/2001	Comments to CMC of SEP 1-B51	Infringement
6.	EOM	10/27/1999	Email from Bailon to Kim re Expert Opinion on Genotox Test Requirement for PEG-EPO	Infringement
7.	EPH	8/17/2001	Report No. 1005851 Regulatory Document, "Long-Lasting Forms of Polyethyleneglycol Conjugated Erythropoietin (PEG-EPO)"	Infringement
8.	EPI		SEP Project RDC 1- 06/13/2002	Infringement
9.	EPV	9/26/2005	An Investigation into the Signaling Pathways Activated by Continuous Erythropoiesis Receptor Activator (CERA) Progress Report #1, September 26, 2005	Infringement
10.	ESU	06/28/1995	Memo from Koll to Scherhag re Cangene - Pegyliertes EPO	Infringement
11.	ETO	09/22/2006	Email from Jarsch to Haselbeck re: Module 4: Non Clinical, Question No. 55: Non Clinical Pharmacology	Infringement
12.	EVI	2/21/2001	[Roche does not object] Patient Informed Consent Form, Roche Protocol No. BA 16260 (Version A)	Infringement
13.	EWU	1/26/2006	Email from Jarsch to Escrig re CERA MOA Abstract for EDTA	Infringement
14.	EXI	01/22/2005	Pre-Clinical Studies on Mode of Action: Summary of Advisory Board, Jan, 22 NY	Infringement
15.	EZC		CERA Modelling Penzberg	Infringement
16.	EZD		CERA Physical and Chemical Characterization	Infringement

## Attachment A

Tab	Ex.	Date	Description	Relevance
17.	EZH	11/4/1999	Email from Bailon to Farid re Description of PEG-EPO	Infringement
18.	EZL	02/03/2004	Email from Haselbeck to Escrig re: Slide for Macdougall about the EPO and CERA and EPO-R	Infringement
19.	FGN	2/18/2002	Email from Bailon to Ehrlich re EPO & PEG-EPO	Infringement
<b>BLA/IND</b>				
20.	GXE	4/18/2006	Letter Submitting BLA for MIRCERA, Form 356h, Table of Contents and Roadmap of BLA	Infringement
21.	GXF		Information for Patients and Caregivers, MIRCERA pegserepoetin alfa FOR INJECTION	Infringement
22.	EAZ-1		Drug Substance – R00503821 <ul style="list-style-type: none"> <li>• ITC-R-BLA 00004024 – 4032</li> <li>• ITC-R-BLA 00004232 – 4244</li> <li>• ITC-R-BLA 00004324 – 4330</li> </ul>	Infringement
23.	EBA-1		Drug Substance – EPO Starting Material <ul style="list-style-type: none"> <li>• ITC-R-BLA 00004651 – 4662</li> <li>• ITC-R-BLA 00004667 – 4669</li> <li>• ITC-R-BLA 00004722 – 4740</li> <li>• ITC-R-BLA 00004803 – 4857</li> <li>• ITC-R-BLA 00004987 – 4988</li> <li>• ITC-R-BLA 00005073 – 5074</li> <li>• ITC-R-BLA 00005580 – 5581</li> <li>• ITC-R-BLA 00005616 – 5619</li> </ul>	Infringement
24.	GXB		Section 2.7.2 of Roche's BLA - Summary of Clinical Pharmacology Studies	Infringement
25.	GXD	8/16/2004	Report No. 1012588, Regulatory Document, RO0503821-000: In vivo stability and tissue localization of RO0503821 after single (IV or SC) or multiple (IV) dose administration to rats (Study Nos. D01017 and D02001)	Infringement
26.	GXC		Investigational New Drug Application, Form 1571 for Ro 50-3821, and Letter Submitting IND	Infringement